Priorities for 2012
AVAC's Playbook 2012 sets out top strategic goals and priorities in HIV prevention for ourselves—and for the world. Here's what we have to say about PrEP. For more, visit www.avac.org/playbook.What's New
Request for FDA Priority Review on
PrEP
25 HIV and health organizations sent a letter
to the FDA requesting priority review for the
labeling change of Truvada for PrEP
- See the letter
- Read AVAC's statement on Gilead's submission of PrEP data to the FDA
VOICE Trial Team Announces Closure of Tenofovir Gel Trial Arm in VOICE Trial; Listen to a Global Teleconference Discussion with Investigators
- MTN Statement
- Questions
and Answers document on DSMB decision (from
MTN)
- AVAC Statement
- Listen
to a recording of a global teleconference
to discuss this development
New PrEP data show TDF and TDF/FTC
effective in men and women
- Global teleconference with trial
investigators was held to discuss these
results. Download an mp3
recording here.
- AVAC's statement on these landmark results
- Statements are available from the trial sponsors—the University of Washington and the CDC.
- Other resources:
- Partners Key Facts Partners PrEP FAQ
- Partners PrEP Backgrounder
- CDC Partners PrEP Factsheet
- Q&A
about Partners PrEP and VOICE
- For background on PrEP, see below
Discontinuation of the FEM-PrEP
Trial Disappointing
Continued research to find new ways to end the
HIV epidemic essential
- Global teleconference held to discuss this
development, recording
available here
- Read AVAC's statement on the trial closure
- Read more statements and background information on FEM-PrEP
- To read more on PrEP background, scroll down to the links below
Background on PrEP
Recent research results shows promise for a new HIV prevention strategy called pre-exposure prophylaxis or PrEP. PrEP involves HIV-negative people at risk for HIV using antiretroviral medications (ARVs) to reduce the risk of HIV infection.
The iPrEx trial results were released in November, 2010 and showed that in gay men, transgender women and other men who have sex with men, daily TDF/FTC (tenofovir disoproxyl fumarate plus emtricitabine also known as Truvada) reduced the risk of HIV by 44 percent. Additional studies are ongoing in other populations.
PrEP is not yet recommended for use. Given that iPrEx tested an already licensed drug, there is the potential for immediate, off-label use. In the US, the Centers for Disease Control and Prevention issued interim guidance on PrEP as an HIV prevention strategy for men who have sex with men.
You can get around the PrEP section via the links below (each list includes a few key resources from the section) or navigation to the left. If you are looking for a specific document, try the search box to the right.
Introductory Information
Ongoing Trials and Recent Results
In-depth PrEP Resources
- A Cascade of Hope and Questions
- CDC Interim Guidelines
- Pushing the PrEP Agenda: AVAC’s take and a report from CROI 2011
- PrEP related webinars